A prognostic factor index for overall survival in patients receiving first-line chemotherapy for HER2-negative advanced breast cancer: an analysis of the ATHENA trial. [electronic resource]
Producer: 20150622Description: 656-62 p. digitalISSN:- 1532-3080
- Adult
- Aged
- Aged, 80 and over
- Antibodies, Monoclonal, Humanized -- administration & dosage
- Antineoplastic Agents -- administration & dosage
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Bevacizumab
- Breast Neoplasms -- drug therapy
- Decision Support Techniques
- Drug Administration Schedule
- Female
- Humans
- Middle Aged
- Prognosis
- Receptor, ErbB-2 -- metabolism
- Risk Assessment
- Risk Factors
- Survival Rate
- Taxoids -- administration & dosage
No physical items for this record
Publication Type: Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.